6,100,000 Shares JUNO THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • September 22nd, 2017 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
SHARE PURCHASE AGREEMENT AND OMNIBUS AMENDMENTShare Purchase Agreement and Omnibus Amendment • September 22nd, 2017 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Share Purchase Agreement and Omnibus Amendment (this “Agreement”) is dated as of September 21, 2017, by and among Juno Therapeutics, Inc., a Delaware corporation (the “Company”), Celgene Corporation (“Celgene Corp.”), Celgene Switzerland LLC (“Celgene Switzerland”) and Celgene RIVOT Ltd (“Celgene RIVOT” and together with Celgene Corp. and Celgene Switzerland, the “Celgene Parties”).
